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Growing resistance to antibacterial agents has
increased the need for the development of new drugs
to treat bacterial infections. Given increasing pressure
on limited health budgets, it is important to study the
cost-effectiveness of these drugs, as well as their
safety and efficacy, to find out whether or not they
provide value for money and should be reimbursed. In
this article, we systematically reviewed 38 cost-effec-
tiveness analyses of new antibacterial agents. Most
studies showed the new antibacterial drugs were cost-
effective compared to older generation drugs. Drug
pricing is a complicated process, involving different
stakeholders, and has a large influence on cost-effec-
tiveness. Value-based pricing is a method to determine
the price of a drug at which it can be cost-effective. It
is currently unclear what the influence of value-based
pricing will be on the prices of new antibacterial
agents, but an important factor will be the definition of
‘value’, which as well as the impact of the drug on
patient health might also include other factors such as
wider social impact and the health impact of disease.
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Since the discovery of the first antibacterial agents in the
1930s, many new antibacterial drugs have been devel-
oped. This has had a large influence on health because
of the decreased mortality and morbidity of bacterial
infections (1,2). Between the 1970s and the 1990s, few
new antibacterial drug classes were launched (3,4). Phar-
maceutical companies were reluctant to invest in the
development of antibacterial agents; the revenues of
the new drugs were expected to be low, because of the
short use of antibacterial drugs and the high competition
with many cheap generic drugs (3,5). The lack of new
antibacterial agents and the growing resistance to the
available drugs has limited the treatment options for infec-
tion in recent years. However, since 2000, a series of
new classes of antibacterial drugs such as oxazolidinones
and lipopeptides have been launched (2–4). Increasingly,
cost-effectiveness is an important factor affecting the
reimbursement of new drugs,a and it is important to
investigate whether these drugs provide value for money.
In this article, we will describe and explain some basic
concepts of cost-effectiveness and review the available
evidence on the cost-effectiveness of new antibacterial
agents. Also, we will provide a brief historical overview of
drug pricing (in the UK) and describe the role of value-
based pricing in determining the price of new antibacterial
agents.
What is Cost-effectiveness Analysis?
In a cost-effectiveness analysis (CEA), the total costs and
effects of two or more treatment options are compared.
When calculating costs, not only should the costs of the
drugs be considered, including administration costs and
costs of treating adverse drug reactions, but also other
costs related to the treatment or disease, such as hospi-
talization costs. To study cost-effectiveness, both incre-
mental (extra) costs and incremental effects are calculated
for the new treatment option compared to the comparator
option, which might be current best practice and which
might be ‘do nothing’. Figure 1 depicts the possible
results of a CEA. Compared with the comparator option,
the new treatment may be more or less costly and more
or less effective. When the new treatment leads to
increased effects while decreasing costs (bottom right
quadrant), it is the dominant treatment option, which
means that it is more attractive than the comparator on
economic grounds. When the new treatment leads to
decreased effect while increasing costs (top left quadrant),
it is dominated by the comparator, which means that the
comparator is a more attractive option. When both costs
and effects are increased (top right quadrant), the attrac-
tiveness of the new treatment depends on how much pay-
ers are prepared to pay for the extra effect. When the
incremental costs per extra unit of effect are lower than
the willingness-to-pay threshold (top right quadrant below
the 45 degree line), the new treatment is cost-effective.
Conversely, when the incremental costs per extra unit of
effect are higher than the threshold (top right quadrant
above the 45 degree line), the new treatment is not cost-
effective. When costs and effects are higher with a new
drug compared with the comparator, the incremental cost-
effectiveness ratio (ICER) can be calculated as shown in
the equation below.
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Calculation of the ICER
ICER =
Cost of new treatment - cost of comparator
Effect of new treatment - effect of comparator
Effectiveness can be measured in many ways usually
related to the treatment goal of the drug (e.g. cure rate).
When effectiveness is measured in terms of cure rates,
cost-effectiveness measured using the ICER is expressed
as the incremental cost per extra case cured. This out-
come measure is, however, very disease-specific, and
therefore, it is difficult to compare with treatments in other
diseases. A recommended measure is quality-adjusted
life-years (QALYs), which account for both quality and
quantity of life.b There are various ways of measuring the
quality of life, including direct valuation methods such as
standard gamble, time trade-off and visual analogue scale
(6) or questionnaires such as the EQ-5D (7). When effects
are measured by QALYs, the ICER is the incremental
cost per QALY gained, and as this is a generic health
outcome measure, it can facilitate comparisons between
treatments for different diseases. For this reason, some
regulatory authorities or health insurance companies
require evidence of a favourable incremental cost per
QALY gained before they approve the use of a new
druga,b. Another generic measure is life-years gained
which is based on life expectancy only and does not take
into account quality of life. This measure is easier to
calculate, because it does not require information on
health-related quality of life impacts, but it is not as com-
prehensive as QALYs.
Whether or not a new treatment is cost-effective depends
on the decision-makers’ willingness to pay for a QALY,
which is different across different settings. In the USA, a
threshold of US$50 000–100 000 per QALY gained is
commonly reported (8); in the UK, a range of
£20 000–30 000 is usedb. Two important issues when
considering cost-effectiveness of a new intervention are
perspective and time horizonb. The perspective is the
viewpoint from which the analysis is performed (e.g.
patient, hospital, healthcare system, society), and this
influences the type of costs that should be collected
(healthcare costs, patient-borne costs, costs borne by the
rest of society, etc.). The time horizon should reflect the
period over which the main differences between two
interventions are expected. In many cases, this is a life-
time horizon. When the time horizon is more than 1 year,
discounting of costs and effects is usually recommended,
which has the effect of giving less weight to costs and
benefits that occur in the future. The recommended dis-
count rates for costs and effects vary by country, for
example, in the UK the discount rates for both costs and
effects should be 3.5% and in the Netherlands the dis-
count rate for costs should be 4% and the discount rate
for effects only 1.5%a.
Every CEA has some level of uncertainty around the
results. This can be because of uncertainty around the
effectiveness estimate or around the costs. There may also
be variability in costs and effects between patients, for
example, because of differences in severity of the disease.
This uncertainty should be assessed in a sensitivity analy-
sis. In a one-way sensitivity analysis, the value of one
parameter is varied over a plausible range, to show the
effect of this parameter on the cost-effectiveness results.
This can be performed for several or all parameters, vary-
ing only one at a time. It is the simplest form of sensitivity
analysis and is useful to identify the parameters with the
largest influence on the results. It is, however, not
regarded as sufficient because it does not take into
account any combined effect of parameters. In a two-way
(or multiway) sensitivity analysis, two (or several) parame-
ters are varied at the same time to assess their joint influ-
ence on the results.
Probabilistic sensitivity analysis is a technique that can be
used to investigate joint parameter uncertainty. It can be
used to generate cost-effectiveness acceptability curves,
showing the chance that a drug would be cost-effective at a
range of cost-effectiveness threshold values. This can be
performed by carrying out a large number of simulations,
drawing random samples from probability distributions for
the ranges of key parameters. The number of simulations
below the cost-effectiveness threshold represents the
chance that the drug would be cost-effective given that
threshold.
Other forms of sensitivity analysis include threshold analy-
sis (identifying a threshold value for a parameter at which
the new treatment would just be cost-effective) and sce-
nario analysis (for example, showing a best-case scenario
and a worst-case scenario).
Figure 1: Cost-effectiveness plane depicting the incremental
costs and incremental effects of the new treatment versus the
comparator.
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Cost-effectiveness of New Antibacterial
Agents
Since 2000, 22 new antibacterial agents have become avail-
able on the market (Box 1) (2). In this section, we will review
the available evidence on the cost-effectiveness of these
new drugs, in comparison to the older antibacterial agents.
Using the NHS Economic Evaluation Database (NHS EED),c
we performed an initial search for CEAs of all 22 new drugs.
Using the drugs in Box 1 as search terms, we identified 41
records. Of these, 12 were excluded, three studies were
published in a non-English language (9–11), one did not con-
cern any of the new drugs (12) and eight did not link costs
and effects explicitly (13–20). Hence, an initial 29 studies
were included for review (21–48, 58). We then undertook a
more extensive search using Embase and PubMed using
the same search terms including cost-effectiveness terms
and found nine additional papers (49–57). Only studies
reporting both costs and effects of the new drug compared
to the comparator were included. Conference abstracts and
non-English papers were excluded. From the papers
included for review, we collected the following information:
year of study, comparator, disease, outcome measure,
whether sensitivity analysis was performed to assess uncer-
tainty and which type of sensitivity analysis and final result
(cost-effective or not). We used the PRISMA guidelines for
systematic searching.
Several CEAs have been published on linezolid, which was
launched in 2000. Other drugs that have been evaluated
are daptomycin, telithromycin, ertapenem, gemifloxacin,
doripenem, telavancin and fidaxomicin (see Table 1).
Cost-effectiveness was always assessed for one specific
indication, such as pneumonia or skin infections caused
by methicillin-resistant staphylococcus aureus (MRSA) or
by other bacteria. Most of the published studies assessed
the incremental cost per extra case cured with the new
antibacterial drug. When both the costs and the cure rate
of the new drug were higher than the comparator (top
right quadrant in Figure 1) (21–23,36,56), it was difficult to
assess whether the new drug was cost-effective or not,
because there is no willingness-to-pay threshold for cost
per extra case cured. In many studies, the new drugs
were more effective, and total costs were lower, which
means that the new treatment was the dominant treatment
(bottom right quadrant in Figure 1). In this case, we can
conclude that the new drug was cost-effective. In some
studies, the authors found that the effectiveness of the
new drug and the comparator were equal, and therefore,
they performed a cost minimization study, only looking at
the cost of the drug versus the comparator.
Nine studies assessed the incremental cost per QALY
gained for linezolid, daptomycin, ertapenem, doripenem
and fidaxomicin (32,33,43,45,48,49,51,52,58). In seven of
these studies, the ICER was below the willingness-to-pay
threshold. In one of these studies, the incremental cost per
QALY gained of fidaxomicin compared to vancomycin was
US$67 576 (45). The authors applied a willingness-to-pay
threshold of US$100 000, so this drug was considered
cost-effective for the treatment of Clostridium difficile infec-
tions.
Most studies showed that the new drugs were cost-effec-
tive, except in four cases. Both linezolid and daptomycin
were dominated by trimethoprim/sulfamethoxazole for the
treatment of MRSA infections (25), and telithromycin was
dominated by moxifloxacin for the treatment of pneumonia
(41). In two studies, on incremental cost per QALY gained,
fidaxomicin was dominated by one or more of the compar-
ators (51,58). All studies correctly considered not only the
costs of the drug itself, but also other costs, such as hos-
pitalization costs, which can affect the ICER.
Because uncertainty is present in every cost-effectiveness
study, a good economic evaluation should perform a sen-
sitivity analysis to examine the robustness of the model
and assumptions. In some studies, no sensitivity analysis
was performed, but most studies included at least some
form of sensitivity analysis. Almost half of the studies
included a probabilistic sensitivity analysis.
Some antibacterial agents can be used for various indica-
tions. The cost-effectiveness, however, has mostly been
studied for one indication at a time. The cost-effectiveness
of the drug can vary between different indications,
because of different bacteria causing the infection or
because of differences in location of the bacteria. It is
therefore necessary to assess the cost-effectiveness of a
new drug for a specific indication, even if the drug can be
used for more than one indication. The cost-effectiveness
Box 1: New antibiotics launched since 2000 (2)
2000 Linezolid 2004 Gemifloxacin 2009 Tebipenem pivoxil
2001 Telithromycin 2005 Doripenem 2009 Telavancin
2002 Biapenem 2005 Tigecycline 2009 Antofloxacin
2002 Ertapenem 2007 Retapamulin 2009 Besifloxacine
2002 Prulifloxacin 2007 Garenoxacin 2010 Ceftaroline fosamil
2002 Pazufloxacin 2008 Ceftobiprole medocaril 2011 Fidaxomicin
2002 Balofloxacin 2008 Sitafloxacin 2012 Bedaquiline
2003 Daptomycin
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of a specific drug might also change over time, when for
example the resistance to the old drugs increases or when
resistance to the new drug develops. The growing resis-
tance to antibacterial agents highlights the urgent need for
the development of new drugs to fight infections.
Value-based Pricing
Pricing of antibacterial drugs is an important topic to con-
sider. For pharmaceutical companies, it is important to
make profit on the sales of these drugs, because of the
large investments needed to develop a new drug. But due
to the limited budget, and the rising proportion of health
spending that is accounted for by pharmaceuticals, good
value for money is an important factor before reimburse-
ment of a new drug. Drug prices are often an important
driver of cost-effectiveness. Additionally, infections occur
more frequently in developing countries with low insurance
coverage where many patients cannot afford expensive
antibacterial drugs. Pricing of the drugs is therefore a
complicated process, involving different stakeholders.
Box 2 shows a historical overview of pharmaceutical pric-
ing in the UK (59). In this section, we provide a brief sum-
mary of this, focusing in particular on value-based pricing.
The timelines and examples are UK specific, but could
easily be applied elsewhere. Many countries use
cost-effectiveness analysis in a similar way to inform reim-
bursement decisionsa, although precise guidelines for
undertaking such evaluations may vary by country.
In the UK, since 1999, the National Institute for Health and
Care Excellence (NICE) appraises the clinical effectiveness
and cost-effectiveness of new drugs. Although this body
has no direct influence on the price, they do give advice
about whether or not drugs (and other healthcare and
public health interventions) should be provided by the
National Health Service (NHS). NICE accounts for several
factors in its decision-making process, but when the incre-
mental costs per QALY gained are higher than £30 000,
NICE normally advises not to include this treatment in the
NHS settingb. As noted, a key driver of cost-effectiveness
is drug price. The Prescription Pricing Regulation Scheme
(PPRS), established in 1957 as the Voluntary Pricing Regu-
lation Scheme, usually negotiates with pharmaceutical
companies to have drugs with a reasonable price which
are still profitable for the pharmaceutical industry. When
NICE would consider a new drug not cost-effective at that
price, pharmaceutical companies may be willing to negoti-
ate a lower price in order to be able to sell the drug in the
NHS setting. In 2002, the government established a risk-
sharing scheme for new multiple sclerosis drugs. These
drugs could be sold at a high price, but if the outcomes of
a cohort study were lower than expected, the price was to
be reduced. This way, the risk of the drug not being cost-
effective was shared by the NHS and the drug company.
Since 2009, it is possible for pharmaceutical companies toT
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negotiate price reductions when the drug is considered
not cost-effective by NICE and therefore not available on
the NHS. A discount is provided, so that the costs of the
new treatment are below the threshold set by NICE and
the treatment can be available on the NHS (patient access
schemes) (59). Also, NICE increased the willingness-to-pay
threshold for drugs extending the life of patients with a
short life expectancy (end of life criteria).
Instead of studying the cost-effectiveness of a drug with a
certain price, NICE could also calculate the maximum price
of the drug at which it would still be cost-effective. When
the price of the drug would be no higher than this threshold
value, it would represent ‘value for money’. Given the fixed
budget of the NHS, money spent on a new drug cannot be
spent elsewhere. With a willingness-to-pay threshold of
£20 000 per QALY gained, we assume that every £20 000
used for a new treatment displaces one QALY elsewhere in
the NHS (60). The QALYs expected to be displaced by a
new treatment can be calculated by dividing the total
expected costs by the willingness-to-pay value. This forms
the basis of value-based pricing. Figure 2 depicts the costs
of a hypothetical new drug that increases health by 2
QALYs compared with the comparator at three different
prices. At price 1, the total extra cost of this treatment to
the NHS is £20 000, which leads to an ICER of £10 000
per QALY gained. So, at price 1, the drug is expected to
improve health by two QALYs and displace 1 QALY (total
costs of £20 000 divided by the willingness to pay of
£20 000) elsewhere in the NHS. The net health benefit,
defined as the difference between the total expected
QALYs and the QALYs expected to be displaced else-
where, would in this case be one QALY (2 expected QALYs
minus 1 QALY displaced elsewhere). At price 2, the total
extra costs of this treatment are £40 000, which leads to an
ICER of £20 000 per QALY gained. Now the drug is still
expected to improve health by 2 QALYs, but displaces 2
QALYs (£40 000) elsewhere. There is no net health benefit
to the NHS. At price 3, the total extra costs of the treatment
are £60 000, which leads to an ICER of £30 000 per QALY.
In this case, 3 QALYs are displaced (£60 000), and the net
health benefits to the NHS are minus 1 QALY (2 expected
QALYs minus 3 QALYs forgone elsewhere). The aim of
value-based pricing is to set the price at a level at which
the net health benefit is positive or zero. A negative health
benefit means that the drug does not provide value for
money. Given that the definition of net health benefit is
the difference between the total expected QALYs and the
Figure 2: Net health benefit of a
hypothetical new drug at three different
prices (60).
Box 2: Historical overview of pharmaceutical pricing in the UK (59)
1957 Voluntary Pricing Regulation Scheme established
1978 Voluntary Pricing Regulation Scheme was renamed to Prescription Pricing Regulation Scheme (PPRS)
1999 NICE established
2002 NICE advices NHS not to provide new multiple sclerosis drugs. The government establishes a risk-sharing scheme
giving patients access to these drugs
2007 Office of Fair Trading recommends value-based pricing for all branded drugs
2008 Government negotiates a scope for price reductions on particular drugs through patient access schemes.
2009 NICE’s end of life criteria raise the willingness-to-pay threshold for these drugs
2010 Government commitment to value-based pricing in next PPRS
2011 Government response to consultation on value-based pricing indicates that it will apply only to new drugs and give
greater role to NICE
2013 Government response to House of Commons Health Committee report confirms NICE to take responsibility for
value-based pricing
Late 2014 Value-based pricing for new drugs appraised by NICE (expected)
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QALYs expected to be displaced elsewhere (total expected
costs divided by the willingness-to-pay value), one could
also say that the aim of value-based pricing is to set the
price of a new drug to a value at which the ICER of that
new drug would be at or below the willingness-to-pay
threshold. In other words, the price can be varied up to the
point at which the incremental cost per QALY is equal to
the threshold.
Value-based pricing was first recommended by the Office
of Fair Trading.d A key issue with value-based pricing is
how ‘value’ is measured. One option would be to express
value as therapeutic value, measured by QALYs. When a
new drug is very effective (it produces a large increase in
QALYs), the drug can be more expensive than when it is
moderately effective (small increase in QALYs). However, it
has been suggested that not only QALYs should be taken
into account when assessing value, and many other fac-
tors could also be included (see Box 3) (61,62). Based on
recent consultation documents produced by NICE,e two
additional components of value that are being given careful
consideration are the burden of disease and the wider
social impact – the impact of disease on people’s ability to
be part of society. Whichever values are included in value-
based pricing, an important consideration is how these
ought to be weighted to account for the fact that different
drugs may have different effects on each factor.
There is little evidence from other countries about the
prospects of value-based pricing, because no country cur-
rently performs value-based pricing as proposed in the
UK. However, in some countries, the insurance coverage
of a new drug is based on the cost-effectiveness of the
drug. In Sweden, insurance coverage depends on
approval from their health technology assessment body
(TLV). For this decision, QALYs as well as production loss
are taken into account.f
Future Prospects
It is unclear yet what the influence of value-based pricing will
be on the prices of new antibacterial agents. If we look at
the different components NICE is planning to consider in
their evaluation, three factors will be of importance; health
gain (QALYs), burden of disease and wider social impact.
Health gain
Many of the studies reviewed in this article showed that
the new antibacterial agents were more effective than the
comparator, mostly because of a higher cure rate.
Because these drugs can be life-saving, a large ‘value’
can be expected for which a high price can be paid.
However, there is currently little evidence about the incre-
mental costs per QALY gained. More evidence is needed
using the effect of new antibacterial agents on QALYs to
set a value-based price for these drugs.
Burden of disease
Because bacterial infections occur frequently, the total
burden of these infections is large. However, as we have
seen in this review, each indication (type of infection)
needs to be considered separately. For some indications,
the burden of disease might be lower than others. In gen-
eral, the burden of one specific bacterial infection is proba-
bly low, also because of the short duration of the illness.
Chronic conditions have a more significant effect on bur-
den of disease than (treatable) acute conditions.
Wider social impact
National Institute for Health and Care Excellence defines
the wider social impact as the loss in capacity of a per-
son with the disease to engage with society (e.g. work-
ing or taking care of someone), compared with their
capacity without the disease. If infections occur among
working people, the impact on productivity might be
high. However, when the duration of the infection is usu-
ally short, the impact will not be as high as for example
with chronic diseases.
Conclusions
Since 2000, several new antibacterial agents have been
developed to treat (resistant) infections such as pneumonia
Box 3: Possible factors to take into account when assessing value (61,62)
Patient or disease-related factors Healthcare process-related factors Factors outside patient + NHS
Severity of disease Treatment time + location Ability to resume working
Near the end of life Waiting times Increased productivity
Size of population Less unpleasant treatment Benefit to carers
No other treatment options Degree of risk of the treatment Cost savings to other services
Socially disadvantaged patients Cost savings to patients/carers
Children Quality of evidence
Reduction in fear (e.g. of death) Innovation
Unmet need
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and skin infections. To keep healthcare spending within
reasonable limits, it is important that new drugs are only
prescribed when these drugs provide value for money.
Most new antibacterial agents are cost-effective alterna-
tives to the old drugs, either because these are more
effective and decrease healthcare costs or the increased
costs are below the willingness-to-pay threshold. Value-
based pricing is a method that could be used to determine
a price for new antibacterial agents at which these drugs
provide value for money.
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